Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:AVDL NASDAQ:DYN NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$21.21+1.2%$23.71$20.39▼$53.96$987.56M0.76454,819 shs440,154 shsAVDLAvadel Pharmaceuticals$11.08+5.4%$9.78$6.38▼$17.30$1.02B1.47986,045 shs993,392 shsDYNDyne Therapeutics$10.05+2.0%$10.71$6.36▼$47.45$1.40B1.082.75 million shs2.75 million shsZYBTZhengye Biotechnology$5.30-4.2%$6.63$3.50▼$14.30$249.98MN/A41,863 shs8,867 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+1.24%-5.19%-10.05%-13.43%-51.26%AVDLAvadel Pharmaceuticals+5.42%+0.45%+25.77%+27.50%-32.19%DYNDyne Therapeutics+2.03%+1.01%+12.42%-15.26%-76.58%ZYBTZhengye Biotechnology-4.16%-4.50%-10.47%-60.68%+529,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.3834 of 5 stars3.12.00.03.73.34.21.3AVDLAvadel Pharmaceuticals2.6701 of 5 stars3.52.00.00.03.41.70.6DYNDyne Therapeutics3.5813 of 5 stars4.52.00.00.03.04.20.0ZYBTZhengye BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3352.44% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.3365.46% UpsideDYNDyne Therapeutics 3.00Buy$36.25260.70% UpsideZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZYBT, DYN, AMPH, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $23.007/29/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$37.00 ➝ $31.007/29/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $38.007/18/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$22.007/15/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/11/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/26/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/25/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/24/2025DYNDyne TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.37$5.06 per share4.19$15.23 per share1.39AVDLAvadel Pharmaceuticals$169.12M6.34N/AN/A$0.77 per share14.39DYNDyne TherapeuticsN/AN/AN/AN/A$4.02 per shareN/AZYBTZhengye Biotechnology$186.36M1.34$0.10 per share53.67$1.02 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.767.686.45N/A19.38%22.20%10.40%8/7/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A184.67N/A-13.58%-36.07%-16.30%8/7/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%8/11/2025 (Estimated)ZYBTZhengye Biotechnology$1.55MN/A0.00∞N/AN/AN/AN/AN/ALatest ZYBT, DYN, AMPH, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025DYNDyne Therapeutics-$0.99N/AN/AN/AN/AN/A8/7/2025Q2 2025AMPHAmphastar Pharmaceuticals$0.71N/AN/AN/A$173.42 millionN/A8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02N/AN/AN/A$60.28 millionN/A7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/A5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.802.952.02AVDLAvadel PharmaceuticalsN/A2.732.33DYNDyne Therapeutics0.1716.8320.35ZYBTZhengye Biotechnology0.011.310.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AVDLAvadel Pharmaceuticals69.19%DYNDyne Therapeutics96.68%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%AVDLAvadel Pharmaceuticals5.20%DYNDyne Therapeutics14.14%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02847.14 million34.18 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableDYNDyne Therapeutics100142.26 million122.15 millionOptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AZYBT, DYN, AMPH, and AVDL HeadlinesRecent News About These CompaniesZhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen5 hours ago | marketbeat.comZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMZhengye Biotechnology Holding LtdJune 21, 2025 | morningstar.comMZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comZhengye Biotechnology faces NASDAQ compliance issueMay 24, 2025 | investing.comZhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing RequirementsMay 23, 2025 | quiverquant.comQZhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-FMay 23, 2025 | globenewswire.comShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the Horizon4 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025View 4 Stocks Planning to Substantially Boost Buybacks After Solid Q2Steel Dynamics Stock Steady on Long-Term ProspectsBy Chris Markoch | July 22, 2025View Steel Dynamics Stock Steady on Long-Term Prospects3 Discounted Steel Stocks You Can DCA Into TodayBy Gabriel Osorio-Mazilli | July 26, 2025View 3 Discounted Steel Stocks You Can DCA Into TodayZYBT, DYN, AMPH, and AVDL Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$21.21 +0.26 (+1.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.38 +0.18 (+0.83%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Avadel Pharmaceuticals NASDAQ:AVDL$11.08 +0.57 (+5.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.02 -0.05 (-0.50%) As of 08/1/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Dyne Therapeutics NASDAQ:DYN$10.05 +0.20 (+2.03%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.17 +0.12 (+1.18%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Zhengye Biotechnology NASDAQ:ZYBT$5.30 -0.23 (-4.16%) As of 08/1/2025 04:00 PM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
